TBRC says Mycobax market enters high-growth phase
TBRC says the global Mycobax market is poised for stronger growth through 2026 as tuberculosis cases rise, healthcare infrastructure expands and demand builds for immunotherapies. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.
Why it matters: - Mycobax targets non-tuberculous mycobacterial infections and tuberculosis, two areas where treatment options remain limited. - Growing demand for immune-based therapies could expand the use case for investigational vaccines in chronic lung disease and high-risk populations. - The market outlook points to broader opportunity in regions with rising tuberculosis burden and improving care access.
What happened: - TBRC said the global Mycobax market is moving into a high-growth phase. - The research company highlighted demand drivers including rising non-tuberculous mycobacterial infections, weak results from traditional antibiotics, and more cases of bronchiectasis and cystic fibrosis. - TBRC also cited stronger investment in immunotherapies, more clinical trials for NTM vaccines, and growing interest in immune-based disease control. - The report says North America held the largest Mycobax market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period.
The details: - Mycobax is an investigational bacillus Calmette-Guérin, or BCG, vaccine designed as an immunotherapy for non-tuberculous mycobacterial infections. - The vaccine is intended to modulate the immune response and help the body fight persistent, often drug-resistant lung infections. - TBRC says Mycobax is aimed especially at patients with bronchiectasis or cystic fibrosis. - Rising tuberculosis incidence is a major market driver. - The CDC reported tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, a gain of 1,295 cases. - TBRC said Mycobax could provide enhanced immunity against mycobacterium tuberculosis, especially where traditional BCG vaccination shows limited effectiveness. - Expanding healthcare infrastructure is another growth catalyst. - The report says more hospitals, clinics, medical devices and trained staff can make it easier to integrate Mycobax into vaccination programs for high-risk groups. - The American Health Care Association said the number of U.S. hospitals rose from 6,093 to 6,129 in May 2023, a 0.591% increase from the prior year. - TBRC said global newborn growth could also support demand for early preventive vaccination. - database.earth projected about 132,399,173 babies will be born worldwide in 2025, including 34,085,338 males and 29,050,646 females. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - TBRC also listed new 2026 report features including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspots infographics, key technology analysis, future trend analysis, and updated graphics and tables. - The company offered a free sample of the report here and the full report here.
Between the lines: - The market story is less about one product launch and more about unmet need in chronic pulmonary infections. - TBRC is framing Mycobax as part of a broader shift toward preventive and immune-based approaches, rather than repeated antibiotic treatment. - The regional split suggests mature markets may lead adoption first, while faster population growth and health spending could drive the steepest expansion elsewhere.
What's next: - TBRC expects continued gains through 2026 as immunotherapy research, vaccine pipelines and clinical trials advance. - Market momentum will likely track tuberculosis incidence, healthcare capacity and uptake of preventive vaccination in high-risk groups. - The report’s forecast period will be shaped by progress in NTM vaccines and treatment approaches for drug-resistant infections.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Market Forecast Reports
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.